FDA Approval Sought to Begin Phase 2 Trial of KM-819

FDA Approval Sought to Begin Phase 2 Trial of KM-819

311059

FDA Approval Sought to Begin Phase 2 Trial of KM-819

FAScinate Therapeutics has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial evaluating KM-819 as a potential therapy for Parkinson’s disease, the company announced in a press release. Parkinson’s disease is characterized by the death and dysfunction of neurons (nerve cells) that produce a chemical messenger called dopamine. KM-819 is an orally active molecule with the potential to be a disease-modifying treatment for Parkinson’s. It inhibits FAF1,…

You must be logged in to read/download the full post.